BioClinica today announced that it has signed a three-year, multi-million dollar agreement for enterprise-wide EDC technology and data management services with a global, multibillion dollar division of a Top 10 pharmaceutical company. Designed for maximum efficiency and flexibility, BioClinica Express will support nearly 200 studies annually for this organization. Together the firms have developed a common data model based on CDISC standards that will facilitate rapid deployment and study closeout while supporting a challenging clinical environment.
The client chose BioClinica Express as part of a broad evaluation of all the leading solutions to achieve its goal of running paperless clinic studies. This agreement marks the second enterprise-level, fullservice EDC agreement that BioClinica has announced this year. BioClinica announced a similar agreement for BioClinica Express and data management services with Cephalon in February.
BioClinica Express is a comprehensive EDC solution that coordinates and organizes the collection and dissemination of clean data, adding speed and quality to the clinical trial process. Express will be used for direct data entry and BioClinica’s full service data management staff will assure that all data is cleaned and processed in a timely manner.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.